Lupin launches Lapatinib Tablets

01 Oct 2020 Evaluate

Lupin has launched Lapatinib Tablets, 250 mg, after Lupin’s alliance partner Natco Pharma received final approval for its ANDA from the United States Food and Drug Administration (USFDA). Lapatinib Tablets, 250 mg, are the generic equivalent of Tykerb Tablets, 250 mg, of Novartis Pharmaceutical Corporation. Lapatinib Tablets (RLD: Tykerb) had annual sales of approximately $61 million in the U.S. (IQVIA MAT June 2020).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2076.90 -28.95 (-1.37%)
05-Jan-2026 14:23 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1732.50
Dr. Reddys Lab 1250.50
Cipla 1517.45
Zydus Lifesciences 918.10
Lupin 2076.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×